How tesamorelin & sermorelin work
One receptor, two lengths
Tesamorelin and sermorelin are both lab-made versions of growth hormone-releasing hormone (GHRH), the brain signal that tells your pituitary gland to release growth hormone. Neither one is growth hormone itself.
When people ask what is sermorelin, the plain answer is human GHRH trimmed to its first 29 amino acids. Tesamorelin keeps the full 44-amino-acid chain and adds a small six-carbon chain at one end.
Tesamorelin has the visceral fat trials, sermorelin has thinner data
Both are GHRH analogs, but only tesamorelin has an FDA-approved brand on the market today, for one narrow use.
- Tesamorelin cut visceral fat 15.2% in a 26‑week HIV trial
- Six weeks of nightly sermorelin left body fat unchanged in older men
- Sermorelin's brand, Geref, was discontinued in 2008
- Peppi's Tesamorelin pen holds 30 mg, and Peppi doesn't sell sermorelin
of tesamorelin in each Tesamorelin pen
Sermorelin: not sold by Peppi
Both bind the same receptor, yet the research behind each one differs, and that gap is where most of the decision sits.
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| What it is | The full 44‑amino‑acid GHRH chain plus a six‑carbon chain | The first 29 amino acids of GHRH |
| How it works | Binds GHRH receptors, raising growth hormone and IGF‑1 | Binds the same receptors to prompt your own growth hormone release |
| Half-life in blood | About 11 minutes in healthy adults (FDA label) | About 4 minutes (disappearance half‑time, a different measure) |
| Main human evidence | Two 26‑week HIV trials, one 12‑month obesity trial | A past pediatric approval, plus small, short studies in older men |
| FDA status | Brand Egrifta is approved only for excess abdominal fat in adults with HIV lipodystrophy | Brand Geref was approved, then discontinued, approvals withdrawn in 2009 |
| At Peppi | Tesamorelin pen, 30 mg | Not sold by Peppi |
| Peppi price | $224 first month on subscription, then $359 every 28 days | Not applicable |
Mechanism alone doesn't settle tesamorelin vs sermorelin. In almost any sermorelin vs tesamorelin search, most of the human trial data you'll find belongs to tesamorelin.
Quality matters as much as the molecule. Your lot number is printed on the pen label, and Peppi's batch test results list potency, sterility, pH and endotoxins for that batch, tested by Accumark Labs and Atlas Analytics.
Tesamorelin benefits for visceral fat
Trials in a narrow group
Tesamorelin's main benefit in research is less visceral fat, the deep fat inside the abdomen. Those trials are why it has an approved use at all.
The best-known tesamorelin results come from adults with HIV who built up abdominal fat during antiretroviral therapy. In a 2007 New England Journal of Medicine trial, 412 patients took tesamorelin or placebo daily for 26 weeks. Visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo.
A 2012 trial looked outside HIV. Sixty adults with abdominal obesity and low growth hormone output took tesamorelin or placebo for 12 months, and visceral fat went down on tesamorelin while it rose on placebo. Fasting glucose and HbA1c didn't change.
Here are the tesamorelin benefits those trials reported, in the people studied:
- Less visceral fat on CT scans
- Lower triglycerides in the 2007 HIV trial
- Lean body mass up about 1.2 to 1.3 kg in the brand's two main trials
- Body weight mostly unchanged
That last point is why the EGRIFTA WR prescribing information says it isn't indicated for weight loss management. The label also notes that tesamorelin raises IGF-1, that glucose intolerance or diabetes may develop, and that joint pain, swelling and injection site reactions are among the most common side effects.

Featured pen
Tesamorelin
30 mg of tesamorelin in a pre-filled, twist-to-dose pen, prescribed only after a licensed clinician reviews your intake.
Daniel M., a verified buyer, put it this way: "I had been doing the right things but still wasn't seeing much change around my waist. My friend recommended Tesamorelin from Peppi and I noticed my clothes started fitting better and I could actually see the progress. Having a clinician check in made it feel a lot more legit than things I'd tried before."
Sermorelin benefits & where it falls short
Real signal, thin results
Sermorelin does raise growth hormone in people. Body composition is another story.
Short hormone studies hold the clearest sermorelin benefits. In a 1992 National Institutes of Health study, 10 healthy older men injected sermorelin twice daily for 14 days. At the higher dose, their growth hormone and IGF-1 levels rose to levels no longer significantly different from young men's.
For body fat, the answer to does sermorelin work is less encouraging. In a 1997 Johns Hopkins study, 11 healthy men aged 64 to 76 used nightly injections for 6 weeks. Growth hormone release went up and two of six strength measures improved, but IGF-1, weight and DEXA measures of muscle and fat stayed the same. Its authors suggested a single nightly dose may work less well than several daily doses.
A 2006 sermorelin clinical review in Clinical Interventions in Aging, written as an editorial, made the case for sermorelin in aging adults. It argued that the body's own brake on growth hormone, a hormone called somatostatin, keeps sermorelin-driven release in pulses and makes overdosing hard. It reports no new trial data.
A 2026 review in Frontiers in Endocrinology was more cautious. It found that meaningful benefits in healthy people remain uncertain, because the human evidence is limited and largely indirect.
Peppi doesn't sell sermorelin. Its other growth-hormone-signaling option is the CJC + Ipamorelin pen, with 10 mg of CJC-1295 (no DAC) and 10 mg of ipamorelin. CJC-1295 without DAC is also a GHRH analog, while ipamorelin works through a different receptor, the ghrelin receptor.
Be clear-eyed about that pen, too. That same 2026 review reports no peer-reviewed human studies of CJC-1295 without DAC itself, which is one more reason a clinician reviews your history first. You can only be prescribed one growth hormone peptide at a time, so the choice is Tesamorelin or CJC + Ipamorelin, never both.

Featured pen
CJC + Ipamorelin
10 mg of CJC-1295 (no DAC) and 10 mg of ipamorelin in one pen, designed to support muscle development, body composition, sleep and recovery.
Tesamorelin dosage vs sermorelin dosage
Labels, not advice
Tesamorelin dosage has a current FDA label behind it. Sermorelin dosage doesn't. Neither one is a number for you to copy.
For EGRIFTA WR, the label sets 1.28 mg injected under the skin of the abdomen once daily. That dose applies only to EGRIFTA WR, a brand formulation for adults with HIV-associated lipodystrophy. It also says EGRIFTA WR and EGRIFTA SV are not substitutable, so dosing doesn't even carry between two brand products.
Sermorelin has no current label to quote. Geref was approved to treat children with growth hormone deficiency and as a pituitary test. Neither approval covered treating adults, and both were withdrawn in 2009.
- Tesamorelin pen: 30 mg of tesamorelin
- A licensed clinician personalizes your dose from your intake
- Twist-to-dose selector, with no mixing or measuring
- One pen is a one-month supply, refilled every 28 days
Peppi's note on timing applies here. Peptide therapy is cumulative, and Peppi recommends committing 4 to 6 months for results to build.
Is sermorelin FDA approved
Approved, then discontinued
Ask is sermorelin FDA approved today, and the answer is no. Under the brand name Geref it held two FDA approvals, and both ended in 2009.
- December 28, 1990: Geref ampules approved to test how well the pituitary secretes growth hormone
- September 26, 1997: Geref vials approved to treat idiopathic growth hormone deficiency in children with growth failure
- 2008: the manufacturer told FDA both products were being discontinued
- June 18, 2009: FDA's withdrawal of both approvals took effect
- March 2013: FDA found Geref wasn't pulled from sale for reasons of risk or effectiveness
That 2013 Federal Register notice rules out risk or effectiveness as the reason Geref left the market, based on the records FDA reviewed. It also lets FDA approve generic versions that refer to Geref, if they meet the usual requirements. FDA's drug database still lists both Geref applications as discontinued, with no other approved sermorelin product.
According to the 2006 editorial, sermorelin couldn't compete with recombinant growth hormone for children's growth, and the manufacturer withdrew it as a treatment.
Tesamorelin's brand, Egrifta, was first approved in 2010 and is still approved, for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Peppi's peptides, its Tesamorelin pen included, are not FDA-approved and are dispensed only with a prescription.
Which GHRH peptide to choose
Start with your goal
For visceral fat, the GHRH peptide with real human trials is tesamorelin. Sermorelin's case rests on short hormone studies and a brand that left the market.
Tesamorelin
Pros
- Large human trials for visceral fat
- An FDA‑approved brand for one narrow use
- Lean mass rose in the brand's trials
Cons
- Main trials were in adults with HIV
- Raises IGF‑1 and can affect blood sugar
- Not indicated for weight loss
Sermorelin
Pros
- Raised growth hormone and IGF‑1 in older men
- Its brand wasn't pulled over risks or effectiveness
Cons
- No body fat change in a 6‑week study
- No FDA‑approved product on the market
- Not sold by Peppi
If deep belly fat is your main goal, Peppi's tesamorelin peptide pen holds 30 mg and is designed to support visceral fat reduction and lean body composition. It's $224 for the first month on subscription, then $359 every 28 days, with a 100% refund if your prescription is not approved.
If muscle, sleep or recovery matter more, or you're still unsure, Peppi's peptide goal quiz matches your goals to a pen. A licensed clinician reviews your intake before anything ships.
Not sure which GHRH peptide fits your goals?
Take the QuizQuestions about tesamorelin vs sermorelin
Frequently asked questions
Short answers on strength, stacking and timing.
Is Tesamorelin Stronger Than Sermorelin?
We found no published trial comparing them head to head, so there's no fair way to call one stronger. Both act on the same pituitary receptor. Tesamorelin has 26-week trials showing less visceral fat, while sermorelin's studies are small and short. In one 6-week study of older men, nightly sermorelin raised growth hormone release but didn't change body fat.
Can You Take Tesamorelin & Sermorelin Together?
That's a question for your clinician, not a stack to plan on your own. We found no published study testing the two together, and both act on the same GHRH receptor. Tesamorelin alone raises IGF-1 and can affect blood sugar, and its label calls for checking both during treatment. Peppi doesn't sell sermorelin, and a licensed clinician reviews your intake before anything ships. You can only be prescribed one growth hormone peptide at a time.
How Long Does Tesamorelin Take to Work?
In the brand trials, visceral fat was measured after 26 weeks of daily use, and the 2012 obesity trial ran 12 months. Peppi's Tesamorelin page describes stages: early signals in weeks 2 to 4, changes that may be easier to measure in months 2 to 3, and a goal of sustaining the benefit in months 4 to 6. Response varies by person.
*These statements have not been evaluated by the Food and Drug Administration. Peppi peptides are dispensed only with a prescription.
Peptide guides from Peppi
Keep reading

















